Neuroanaesthesia & neurocritical care
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial
Primary result · Early VAPResult — go to the resultHazard ratio 0.60 95% CI 0.38–0.95Authors' conclusion
In patients with acute brain injury, a single ceftriaxone dose decreased the risk of early VAP.
Study context
- Population
- Comatose (GCS ≤12) adults requiring mechanical ventilation for at least 48 h after acute brain injury, nine ICUs in eight French university hospitals; no selective oropharyngeal and digestive tract decontamination319 analysed
- Participants
- 345 participants
- Comparison
- Single IV ceftriaxone 2 g vs placebo within 12 h of tracheal intubation
- Ceftriaxonen = 171
- Placebon = 174reference
- Primary endpoint
- Proportion of patients developing early ventilator-associated pneumonia (VAP), confirmed by masked assessors
- Follow-up
- 2nd to 7th day of mechanical ventilation
Methodological detailsmulticentre, double-blind, placebo-controlled, assessor-masked, superiority
- Multicentre
- Double-blind
- Placebo-controlled
- Assessor-masked
- Superiority
Primary result
Early VAP
Hazard ratio
0.60
95% CI 0.38–0.95
P = 0.030
Events by treatment group
Ceftriaxone vs Placebo
HR 0.60 (95% CI 0.38–0.95); P = 0.030
As reported in the abstract
Further findings
- No microbiological impact
Safety
- No adverse effects attributable to ceftriaxone
Original publication
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. Lancet Respir Med. Published 20 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →